Vontobel Holding’s PTC Therapeutics PTCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-7,620
Closed -$468K 1509
2025
Q3
$468K Buy
7,620
+84
+1% +$4.38K ﹤0.01% 970
2025
Q2
$368K Sell
7,536
-3,320
-31% -$158K ﹤0.01% 990
2025
Q1
$553K Sell
10,856
-676
-6% -$33.7K ﹤0.01% 754
2024
Q4
$521K Buy
+11,532
New +$494K ﹤0.01% 778
2023
Q4
Sell
-23,513
Closed -$527K 1158
2023
Q3
$527K Sell
23,513
-922
-4% -$34.3K ﹤0.01% 753
2023
Q2
$994K Buy
+24,435
New +$1.2M 0.01% 598
2022
Q4
Sell
-35,425
Closed -$1.78M 1114
2022
Q3
$1.78M Sell
35,425
-2,026
-5% -$99.3K 0.02% 426
2022
Q2
$1.51M Buy
37,451
+5,770
+18% +$202K 0.02% 440
2022
Q1
$1.18M Sell
31,681
-1,378
-4% -$53.1K 0.01% 565
2021
Q4
$1.32M Buy
+33,059
New +$1.27M 0.01% 557
2021
Q2
Sell
-23,226
Closed -$1.1M 1174
2021
Q1
$1.1M Buy
23,226
+125
+0.5% +$7.42K 0.01% 510
2020
Q4
$1.48M Buy
+23,101
New +$1.36M 0.01% 461

Other funds holding PTCT

Vontobel Holding's PTCT Position: Q4 2025 in Review

Vontobel Holding sold out of PTC Therapeutics (PTCT) in Q4 2025, closing a stake of 7,620 shares — an estimated $468K sold.

Vontobel Holding first reported a position in PTCT in Q4 2020 and held it in 12 quarters. The position peaked at $1.78M in Q3 2022. 353 funds tracked by Wall St. Rank hold PTCT as of Q4 2025.

  • Vontobel Holding reported no remaining PTC Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Vontobel Holding sold 7,620 PTC Therapeutics shares in Q4 2025, an estimated $468K.
  • Vontobel Holding first reported a position in PTC Therapeutics in Q4 2020 and held it in 12 quarters.
  • Vontobel Holding's PTC Therapeutics position peaked at $1.78M in Q3 2022.
  • 353 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2025.

Based on Vontobel Holding's 13F filing for Q4 2025, filed 13 Feb 2026.